Thursday, November 12, 2026 | OneTrader US Earnings Report
US corporate earnings on Thursday brought important results from artificial intelligence infrastructure, investment management, biotechnology, mining and engineering services. Nebius Group reported an extraordinary increase in revenue as demand for AI computing continued to expand, while Brookfield Corporation delivered stronger distributable earnings and increased its quarterly shareholder returns.
Ascendis Pharma reported rapid growth in product sales, supported by its expanding rare disease portfolio. Twist Bioscience also announced record annual revenue, with improving gross margins and a positive adjusted EBITDA quarter. After Wednesday’s market close, Tetra Tech, Corteva and Franco-Nevada delivered results that offered a contrasting picture of infrastructure demand, agricultural pricing and precious metals profitability.
1. Nebius Group: Revenue Surges 571% as AI Infrastructure Expands
Nebius Group reported third-quarter revenue of $980.8 million, compared with $146.1 million in the corresponding period last year. The 571% increase reflects the rapid expansion of its AI cloud infrastructure business and growing demand from companies requiring computing capacity for artificial intelligence workloads.
Also Read: US Top Earnings Today, November 11, 2026: CoreWeave, CGI, Alcon, Petrobras and More
Adjusted EBITDA reached $465.8 million, compared with a loss of $5.2 million a year earlier. The company also narrowed its continuing operations net loss to $37.5 million from $119.6 million.
| Financial metric | Q3 2026 |
|---|---|
| Revenue | $980.8 million |
| Revenue growth | 571% |
| Adjusted EBITDA | $465.8 million |
| Continuing operations net loss | $37.5 million |
| Adjusted net income | $90.9 million |
| FY2026 revenue guidance | $3.0B-$3.4B |
| FY2027 revenue guidance | $12B-$13B |
The company expects 2026 revenue toward the lower end of its existing guidance range because some third-party computing capacity additions have been delayed. It also increased its 2026 capital expenditure outlook to approximately $27 billion.
Nebius expects revenue of $12 billion-$13 billion in 2027, signalling that management continues to anticipate substantial expansion. The key consideration for investors is whether the company can convert its rapidly growing infrastructure business into sustainable earnings without allowing financing and construction costs to overwhelm operating progress.
2. Brookfield Corporation: Distributable Earnings Rise 16%
Brookfield Corporation delivered a strong third-quarter performance, with distributable earnings increasing 16% to $1.72 billion from $1.49 billion in the previous year’s quarter.
Distributable earnings before realizations increased to $1.50 billion, while earnings per share before realizations climbed 14%. Its asset management business raised $25 billion during the quarter, supporting growth in fee-bearing capital and recurring management income.
| Financial metric | Q3 2026 |
|---|---|
| Revenue | $20.69 billion |
| Revenue growth | 9.4% |
| Net income attributable to shareholders | $1.31 billion |
| Distributable earnings | $1.72 billion |
| Distributable earnings growth | 16% |
| Distributable earnings per share | $0.73 |
| Earnings before realizations per share | $0.64 |
| Fee-bearing capital | $682 billion |
Brookfield’s wealth solutions business recorded 22% earnings growth, while its asset management division continued to benefit from fundraising activity.
The results demonstrate the importance of recurring management fees, insurance-related earnings and cash-generating operating businesses in Brookfield’s diversified investment model.
3. Ascendis Pharma: Product Revenue Climbs 89% to €366 Million
Ascendis Pharma reported strong third-quarter product revenue growth, supported by increasing commercial demand for its rare endocrine disease treatments.
Product revenue reached €366 million, an increase of 89% from the corresponding period last year. YORVIPATH remained the largest contributor, generating €291 million, while SKYTROFA delivered €59 million and YUVIWEL contributed €16 million.
| Financial metric | Q3 2026 |
|---|---|
| Product revenue | €366 million |
| Product revenue growth | 89% |
| YORVIPATH revenue | €291 million |
| SKYTROFA revenue | €59 million |
| YUVIWEL revenue | €16 million |
The company also reported positive European regulatory committee recommendations for TransCon CNP, its investigational treatment for achondroplasia.
The strong commercial performance gives Ascendis a growing revenue base, while its pipeline offers additional opportunities. Investors will be watching whether the company can maintain its product growth and translate expanding sales into improving overall profitability.
4. Twist Bioscience: Record Annual Revenue Reaches $459 Million
Twist Bioscience reported record revenue of $459.4 million for fiscal 2026, representing an increase of 22% from the previous financial year.
Also Read: US Top Earnings Today, November 5, 2026: AppLovin Surges, Qualcomm Slows and Industrials Deliver
Fourth-quarter revenue reached $126.6 million, up approximately 28% from $99 million a year earlier. The company also reported improving gross margins, reflecting stronger operating efficiency and its growing synthetic biology business.
| Financial metric | Q4 FY2026 / FY2026 |
|---|---|
| Q4 revenue | $126.6 million |
| Q4 revenue growth | 28% |
| FY2026 revenue | $459.4 million |
| FY revenue growth | 22% |
| FY gross margin | 52.4% |
| Q4 adjusted EBITDA | Positive |
| FY2027 revenue guidance | $550M-$560M |
| Q1 FY2027 revenue guidance | $130M-$132M |
Twist expects full-year fiscal 2027 revenue growth of approximately 21% at the midpoint of its guidance. First-quarter revenue is expected to increase approximately 26% year over year at the midpoint.
The combination of record revenue, expanding margins and positive quarterly adjusted EBITDA represents an important development in the company’s profitability trajectory.
Wednesday After-Close Results
The following companies released their results on Wednesday, November 11, after the US market closed. They are included here because their financial reports had not been covered in the previous OneTrader earnings articles.
Also Read: US Top Earnings Today, November 4, 2026: AI Growth, Healthcare Recovery and Industrial Strength
5. Franco-Nevada: Quarterly Profit Climbs 38% on Higher Gold and Oil Prices
Franco-Nevada delivered stronger third-quarter earnings as higher gold and oil prices lifted royalty and streaming revenue. Revenue increased 13% to $549.3 million, while net income reached $395.5 million, compared with $287.5 million a year earlier.
Adjusted earnings per share came in at $1.89, exceeding market expectations. Precious metal deliveries were lower than the previous year, but stronger commodity prices helped offset the volume decline.
| Financial metric | Q3 2026 |
|---|---|
| Revenue | $549.3 million |
| Revenue growth | 13% |
| Net income | $395.5 million |
| Net income growth | 38% |
| Diluted EPS | $2.05 |
| Adjusted EPS | $1.89 |
| Gold equivalent ounces | 130,435 |
| FY2026 sales guidance | 525,000-555,000 GEOs |
Franco-Nevada narrowed its annual gold equivalent sales guidance and said it was tracking toward the middle of its updated range. Its diversified royalty portfolio continues to provide exposure to precious metals and energy without the operating responsibilities of conventional mining companies.
6. Tetra Tech: Record Quarterly EPS and Higher Infrastructure Backlog
Engineering and consulting company Tetra Tech reported fourth-quarter fiscal 2026 revenue of $1.34 billion, while net revenue reached $1.15 billion. Adjusted EPS increased 9% to $0.49, setting a quarterly record.
Also Read: US Top Earnings Today, November 3, 2026: Apple, Palantir, Pfizer and Major Quarterly Reports
The company benefited from demand for water infrastructure, environmental services and government engineering projects. Its adjusted EBITDA margin also expanded by 90 basis points year over year.
| Financial metric | Q4 FY2026 |
|---|---|
| Revenue | $1.34 billion |
| Net revenue | $1.15 billion |
| Net revenue growth* | 5% |
| GAAP EPS | $0.51 |
| Adjusted EPS | $0.49 |
| Adjusted EPS growth | 9% |
| Adjusted EBITDA | $194 million |
| Backlog | $4.67 billion |
*Net revenue growth excluding episodic disaster response.
For fiscal 2027, Tetra Tech expects adjusted earnings per share of $1.65-$1.80 and net revenue of $4.425 billion-$4.625 billion.
The higher backlog provides visibility into future project activity, particularly in water management and sustainable infrastructure.
Also Read: US Top Earnings Today, November 2, 2026: Marriott, Estée Lauder, Fox and More
7. Corteva: Sales Decline 9% as Agricultural Pricing Pressures Continue
Corteva reported third-quarter net sales of $1.59 billion, a 9% decline from the previous year. The agricultural technology company’s results reflected weaker market conditions in Brazil and pricing pressure across selected crop protection products.
Adjusted operating EBITDA declined 17% to $220 million, while adjusted operating EPS fell 57% to $0.06. The decline in agricultural sales demonstrates how regional demand, crop economics and pricing competition can affect earnings even when new product sales remain healthy.
| Financial metric | Q3 2026 |
|---|---|
| Net sales | $1.59 billion |
| Revenue growth | -9% |
| GAAP EPS | -$0.08 |
| Adjusted operating EPS | $0.06 |
| Adjusted operating EPS growth | -57% |
| Adjusted operating EBITDA | $220 million |
| FY2026 adjusted EPS guidance | $0.76-$0.80 |
| FY2026 adjusted EBITDA guidance | $1.10B-$1.125B |
Corteva lowered its full-year outlook, reflecting weaker-than-anticipated market conditions in Brazil. The revised guidance makes the company’s ability to stabilise pricing and improve regional demand particularly important for its next reporting period.
8. Vylor: Seed Business Faces Lower Quarterly Sales and Higher Operating Losses
Vylor reported third-quarter pro forma net sales of $938 million, down 1% from $944 million in the previous year. Organic sales declined 3%, with lower volumes across its international operations offset partly by improved price and product mix.
Also Read: US Weekly Earnings Review: Microsoft, Alphabet, Amazon, Intel and Major Q3 Results (Oct 26–30, 2026)
The company reported a pro forma loss from continuing operations of $480 million, compared with a loss of $391 million a year earlier. Adjusted pro forma operating EBITDA also deteriorated, reflecting weaker operating leverage.
| Financial metric | Q3 2026 |
|---|---|
| Pro forma net sales | $938 million |
| Revenue growth | -1% |
| GAAP pro forma EPS | -$0.72 |
| Adjusted pro forma operating EPS | -$0.42 |
| Adjusted operating EBITDA | -$269 million |
| Organic sales growth | -3% |
Despite the weaker quarterly performance, Vylor reaffirmed its full-year 2026 guidance. Its year-to-date adjusted operating EPS increased 6%, supported by improved licensing income and performance in selected agricultural markets.
The company’s results highlight the pressure on agricultural businesses from changing planting patterns, weather conditions and lower crop protection volumes.
What the Latest Earnings Tell Investors
Thursday’s earnings provide a useful comparison between companies benefiting from structural demand and those facing more difficult operating conditions.
Also Read: US and UK Earnings Today: Amazon, Exxon, Chevron and AstraZeneca Lead Major Results
Nebius is expanding rapidly as businesses invest in AI computing capacity, but its infrastructure spending and capacity delivery schedule remain important risks. Brookfield continues to generate higher distributable earnings through its investment and asset management operations. Ascendis and Twist are demonstrating growth in specialised healthcare markets, with expanding product sales and improving commercial performance.
Wednesday’s after-close reports add another dimension. Franco-Nevada benefited from higher commodity prices, Tetra Tech continued to gain infrastructure work, while Corteva and Vylor faced agricultural market pressures.
The broader earnings lesson is straightforward: strong revenue growth matters, but investors should also assess whether companies can protect margins, control financing costs and generate sustainable earnings per share. These factors will remain central to evaluating the quality of corporate results through the remainder of the reporting season.
Disclaimer: This article is intended for educational and informational purposes only. It does not constitute investment advice, financial advice or a recommendation to buy, sell or hold any securities. Readers should conduct their own research or consult a qualified financial adviser before making investment decisions. OneTrader is not registered with SEBI as an investment adviser.
Also Read: Top US Earnings Today, October 29, 2026: Lilly, Mastercard, Caterpillar, Merck, Quanta and More
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
Need a laugh after all that money talk?
Paisa LOL: India's funniest finance page, with memes, comics, jokes and long funny stories.
